OCD Clinical Trial
Official title:
Individual Versus Group Exposure and Response Prevention Therapy for the Treatment of Obsessive-Compulsive Disorder
The primary objective is to examine the efficacy of implementing evidence based Exposure and Response Prevention (ERP) within group therapy versus individual therapy by monitoring reduction of Obsessive-Compulsive Disorder (OCD) symptomology.
The purpose of the following study is to observe the effectiveness of group Exposure and
Response Prevention verses individual Exposure and Response Prevention on patients with OCD
for the use of future publications.
A total of 70 individuals will be recruited through different methods. The primary
recruitment sources will be through BCM Psychiatric Clinic patient flow. Although it is
anticipated that most of the study recruitment will occur through normal BCM Psychiatric
Clinic patient flow, study advertisements will also be circulated through several relevant
sources (e.g. BCM OCD Program website, Peace of Mind Foundation website and listserv, social
media pages and OCD organizations and groups). The investigators will also contact clinicians
and professionals working with OCD patients (e.g., private clinics, community organizations)
in the community to distribute advertisement flyers to potential participants.
Enrollment will occur in person at Baylor College of Medicine after obtaining informed
consent.
Pertinent clinical information will be collected from paper or electronic medical records.
Demographics (race, ethnicity, gender, education, employment status), and health history
(concomitant medical history) will be collected and entered in the database. Data entered in
the database will be coded. Patient identifying information such as name, address, telephone,
date of birth, and medical record number will be extracted from the medical record. A study
ID will be assigned to each subject. The code linking the consented subjects' clinical
information to their study ID will be stored in a password protected database. The code
linking key containing patient identifying information will be kept separately from the
database. Any relevant paperwork, including videos, will be stored in a locked file cabinet
in the PIs office.
Prospective data collection will continue for those subjects that consent to participate in
the study.
Investigators wishing to utilize the information collected in this database must show proof
of an IRB approved protocol that will be reviewed by the PI of this database registry before
information can be released. Depending on the purpose of the research, data will be shared
without identifiers if possible. If requested, data can be sent coded to the investigator.
Only those subjects that fit inclusion criteria for the proposed research and specify that
they consent to be contacted about other research will be shared with the other requesting
investigators. Other investigators will not have access to the document that links coded data
to identifiers.
Participants will be randomly assigned (1:1) to receive either individual therapy (i.e., 12
individual ERP sessions, each 45-60 minutes, offered twice weekly for a total of six weeks)
or group therapy (a total of 6 group ERP sessions, each 120 minutes, offered weekly for 6
weeks). Sessions will be led by an ERP trained mental health professional or trainee under
the supervision of a licensed mental health professional. Both the individual and group
participants will receive a total of 12 hours of ERP over the span of six weeks. However,
those assigned to group therapy will meet for 2 hours weekly versus those assigned to
individual therapy will meet for 1 hour twice weekly. Each session will consist of completed
measures and therapy involving ERP for the entirety of the six weeks. Participants assigned
to the group therapy protocol will be placed in groups, each consisting of 5-8 individuals,
with two therapists per group.
In the groups, Session 1 will focus on psychoeducation about ERP and OCD. Sessions 2-5 will
involve ERP tasks. Session 6 will focus on relapse prevention strategies. In individual
treatment, Session 1 will focus on psychoeducation, sessions 2-10 on ERP, 11-12 on relapse
prevention.
All patients will voluntarily participate in assessments with the researcher while also
completing self-reported measures. All clinician-rated assessments will be conducted with an
independent evaluator (IE). The demographic data will be collected at the beginning of
treatment, Baseline. The Y-BOCS and self-report Y-BOCS will be administered at Baseline and
Post-treatment. The Clinical Global Impression-Severity, OCD Identity Questionnaire, Sheehan
Disability Scale, Depression Anxiety Stress Scale-21 (DASS-21) Item Version and the Quality
of Life (Q-LESQ-SF)-21 will be administered at Baseline, Mid treatment and Post-treatment to
track patient symptomology. The weekly feedback measure will be administered every session to
participants to collect data on their thoughts of how treatment is going. The following list
of measures will be administered.
Researcher Administered:
1. Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
2. Self-report Yale-Brown Obsessive-Compulsive Scale
3. NIMH Global Obsessive-Compulsive Scale (NIMH-GOCS)
4. Clinical Global Impression-Severity/Improvement *
Self-Administered:
1. Demographic Form - Baseline
2. Sheehan Disability Scale- Baseline, Mid treatment and Post-treatment
3. OCD Identity Questionnaire- Baseline, Mid treatment and Post-treatment
4. Depression Anxiety Stress Scale - 21 Item Version (DASS-21) - Baseline, Mid treatment
and Post-treatment
5. Quality of Life-21 (Q-LESQ-SF) - Baseline, Mid treatment and Post-treatment
6. Weekly Feedback Measure - Every session
The investigators will enroll all eligible subjects. A total of 70 individuals will
participate. This number is anticipated based on group and individual dyad enrollment.
Descriptive analyses of participant data will be ongoing for one year, the entire duration of
the study. For this study, descriptive statistics and symptomology improvements/ regressions
analyses will be used to analyze study variables. Measures will be analyzed for use of future
publications surrounding ERP treatment for OCD in groups and individual settings.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00215137 -
Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder
|
Phase 2 | |
Recruiting |
NCT06050369 -
Objective Characterizatoion of Repetitive Behaviors
|
N/A | |
Recruiting |
NCT06347978 -
Personalized DBS for OCD Guided by Stereoencephalography Mapping
|
N/A | |
Recruiting |
NCT05712057 -
Neurostimulation Versus Therapy for Problems With Emotions
|
N/A | |
Not yet recruiting |
NCT03313622 -
Locating Biomarkers in OCD Through Behavioral Tasks
|
||
Withdrawn |
NCT03842345 -
DELPhI Evaluation of Psychiatric Conditions
|
||
Completed |
NCT02866422 -
Development of an Instrument That Monitors Behaviors Associated With OCD
|
N/A | |
Completed |
NCT01833442 -
Randomized Controlled Meditation Trial for Treating OCD
|
N/A | |
Recruiting |
NCT04904952 -
Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients
|
N/A | |
Completed |
NCT05981690 -
Therapist Guided, Parent-led, Cognitive Behavioural Therapy (CBT) for Preadolescent Children With Obsessive Compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT02500888 -
Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT06244121 -
Effect of Pyridoxine as Add-on Therapy in OCD Patients
|
N/A | |
Recruiting |
NCT05580614 -
Paired tVNS With ERP in OCD
|
N/A | |
Active, not recruiting |
NCT03511534 -
Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT05624528 -
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
|
Phase 2 | |
Recruiting |
NCT05881356 -
Discovering Factors in the Clinical Study Journey of Patients With OCD
|
||
Recruiting |
NCT05359562 -
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
|
N/A | |
Recruiting |
NCT03459456 -
Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)
|
||
Active, not recruiting |
NCT05930912 -
Psychiatric Orders in Psychoanalytic Treatment of ASD
|